Tags : Option

MedTech

Qiagen Collaborate with TScan to Develop T Cell-Based COVID-19 Test

Shots: TScan signs exclusive research and option to license agreement with Qiagen to develop T cell-based laboratory tests for detecting prior exposure to the SARS-CoV-2 Qiagen gets an option to license the rights and IP for several of TScan discovered immunodominant T cell targets, associated sequences and relevant data for the development and commercialization of […]Read More

Biotech

BMS Exercises its Option to Globally License Obsidian’s CD40L Cell

Shots: BMS has exercised its option to an exclusive WW license to a cell therapy based on Obsidian’s cytoDRiVE technology for the controlled expression of the immunomodulatory factor CD40L In 2019, the companies collaborated to develop novel cell therapies, under which Obsidian is eligible to receive milestones and royalties on sales of therapies. Exercising the […]Read More

Pharma

AbbVie Exercises its Option to License Morphosys’ αvβ6 Integrin Inhibitor

Shots: Morphic will receive a $20M as license fee and is eligible to receive milestones and royalties on sales of any commercialized therapy while AbbVie has exercised a license option under the companies’ R&D collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors for fibrotic diseases including IPF and additional indications The license covers αvβ6 integrin […]Read More

Pharma

AbbVie Signs an Exclusive Worldwide Option and License Agreement with

Shots: Alpine to receive $60M up front, ~$805M as option exercise fee, development, regulatory and commercial milestones along with royalties on net sales of ALPN-101 AbbVie to get an option to exclusively license ALPN-101, following exercising the option, AbbVie will conduct all future clinical development, manufacturing, and commercialization activities for ALPN-101 During the option period, […]Read More

Pharma

Roche Signs an Exclusive Worldwide Option and License Agreement with

Shots: Vividion to receive $135M upfront in cash and is eligible to receive billion dollars preclinical, development and commercial milestones along with royalties on sales of commercialized products resulting from the collaboration Vividion will be responsible for early drug discovery and pre-clinical development for selected programs and has the right to conduct clinical development up […]Read More

Pharma

Immunic Exercises its Worldwide Exclusive Option to License for IMU-856

Shots: Immunic has exercised its exclusive option to license a group of compounds for Daiichi’s IMU-856. Daiichi to receive up front, certain future development, approval & sales milestone payments plus royalties on IMU-856. Immunic to get exclusive commercialization rights for IMU-856 in all countries, including the US, EU, and Japan Additionally, the option includes patent […]Read More